Reviews and feature articlesGuideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education Network
Section snippets
The Beta Agonist Study
In the early 1990s, because of observations made primarily with the use of fenoterol, considerable controversy existed regarding the safety of regular β2-agonist use in asthma. Some investigators reported that the regular use of this class of compounds had the potential of increasing both morbidity and mortality from asthma,2 whereas others were not convinced that such angst was warranted.3 To directly address this controversy, the first protocol developed by the ACRN was the Beta Agonist Study
The Prevention of Early Asthma in Kids trial
Based on data generated in both pediatric28 and adult26, 34 patients with asthma, current asthma guidelines recommend that daily controller therapy should be initiated in individuals whose symptoms place them in the mild persistent asthma category. However, in preschool-aged children wheezing is a common manifestation of viral respiratory tract infections,35 and properly diagnosing asthma in this age group so that appropriate treatment can be initiated has posed a challenge for many clinicians.
Summary
This review has highlighted the major contributions of the ACRN and CARE Network trials to the current NAEPP asthma treatment guidelines, as depicted in Fig 1. First, the stepwise positioning (level of severity between intermittent and persistent) of as-needed short-acting β2-agonists was established (BAGS), and later, whether a subgroup of patients might be at risk if these agents were used on a regular basis (the BARGE trial) was established. Second, the use of the long-acting β-agonist
References (45)
Perspectives in beta 2-agonist therapy: vox clamantis in deserto vel lux in tenebris?
J Allergy Clin Immunol
(1995)- et al.
Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
Lancet
(1994) - et al.
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial
Lancet
(2004) - et al.
Significant variability in response to inhaled corticosteroids for persistent asthma
J Allergy Clin Immunol
(2002) - et al.
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial
Lancet
(2003) - et al.
Effect of early vs late intervention with inhaled corticosteroids in asthma
Chest
(1995) - et al.
Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children
Respir Med
(1994) - et al.
Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies
J Allergy Clin Immunol
(2004) - et al.
A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial
J Allergy Clin Immunol
(1992) - et al.
Tucson Children's Respiratory Study: 1980 to present
J Allergy Clin Immunol
(2003)
Impulse oscillometry provides an effective measure of lung dysfunction in 4-year-old children at risk for persistent asthma
J Allergy Clin Immunol
Characterization of within-subject responses to fluticasone and montelukast in childhood asthma
J Allergy Clin Immunol
Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma
J Allergy Clin Immunol
The clinical trials in the initial five-year award period of the Asthma Clinical Research Network
Control Clin Trials
The use of beta-agonists and the risk of death and near death from asthma
N Engl J Med
Comparison of regularly scheduled with as-needed use of albuterol in mild asthma
N Engl J Med
A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma
N Engl J Med
Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma
JAMA
Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial
JAMA
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
Am J Respir Crit Care Med
Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma
Thorax
Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial
JAMA
Cited by (0)
(Supported by an unrestricted educational grant from Genentech, Inc. and Novartis Pharmaceuticals Corporation)
Series editor: Harold S. Nelson, MD
The Asthma Clinical Research Network (I) is supported by National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) grants 5U10HL051845, 5U10HL051831, 5U10HL051834, 5U10HL051843, 5U10HL056443, 5U10HL051810, and 5U10HL051823. The Childhood Asthma Research and Education Network is also funded by NIH/NHLBI through grants 5U10HL064313, 5U10HL064288, 5U10HL064305, 5U10HL064295, 5U10HL064287, and 5U10HL064307.
Disclosure of potential conflict of interest: R. F. Lemanske, Jr, has consultant arrangements with Aventis, GlaxoSmithKline, Merck, and AstraZeneca; has received grant support from the National Heart, Lung, and Blood Institute (NHLBI); and is on the speakers' bureau for Novartis, Merck, GlaxoSmithKline, and AstraZeneca. C. A. Sorkness has consultant arrangements with AstraZeneca and GlaxoSmithKline; has received grant support from GlaxoSmithKline; and is on the speakers' bureau for GlaxoSmithKline. V. M. Chinchilli has consultant arrangements with BristolMeyers Squibb and Eli Lilly and has received grant support from the NHLBI. L. C. Denlinger has declared that he has no conflict of interest.